PORTLAND — Attorney General Janet T. Mills says the MaineCare program will be reimbursed more than $74,000 under a settlement between Allergan Inc. and the federal government and states over how the company markets Botox.

Allergan agreed to pay $600 million to settle a federal investigation into the marketing of its wrinkle-smoothing drug Botox. The U.S. Justice Department says Allergan acknowledged marketing Botox to physicians for unapproved uses including headaches, spasticity, crossed eyes and underarm sweating.

The investigation was sparked by a whistleblower complaint.

California-based Allergan also reached an agreement with the Department of Health and Human Services’ Office of the Inspector General that requires the company to submit compliance reports.